Skip to Content
Merck
CN

SML2260

Taspoglutide trifluoroacetate salt

≥95% (HPLC), GLP-1 receptor agonist, lyophilized powder

Synonym(s):

8-(2-Methylalanine)-35-(2-methylalanine)-36-L-argininamide-7-36-glucagon-like peptide I (human) trifluoroacetate salt, BIM 51077 trifluoroacetate salt, R1583 trifluoroacetate salt, RO 5073031 trifluoroacetate salt, [Aib8,35]hGLP-1(7-36)NH2; H-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2 trifluoroacetate salt

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C152H232N40O45 · xC2HF3O2
CAS Number:
275371-94-3
Molecular Weight:
3339.71 (free base basis)
UNSPSC Code:
51111800
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Taspoglutide trifluoroacetate salt, ≥95% (HPLC)

assay

≥95% (HPLC)

form

lyophilized powder

color

white to beige

shipped in

wet ice

storage temp.

−20°C

Related Categories

Biochem/physiol Actions

Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist. Taspoglutide improves glucose tolerance, postprandial glucose, body weight, glycaemic control and insulin sensitivity in the Zucker diabetic fatty rat.
long-acting glucagon-like peptide 1 (GLP-1) receptor agonist

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000316168
0000249135
0000249135
0000316168
0000043581

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

S R K Seshasai et al.
Diabetes, obesity & metabolism, 17(5), 505-510 (2015-02-07)
To study the short-term cardiovascular effects of the once-weekly glucagon-like peptide-1 receptor agonist taspoglutide. We conducted a meta-analysis of individual-participant data from nine randomized controlled trials in the T-Emerge programme, which assessed the efficacy and safety of taspoglutide in type
E Sebokova et al.
Diabetes, obesity & metabolism, 12(8), 674-682 (2010-07-02)
Glucagon-like peptide-1 (GLP-1) receptor agonists are a novel class of pharmacotherapy for type 2 diabetes. We investigated the effects of a novel, long-acting human GLP-1 analogue, taspoglutide, in the Zucker diabetic fatty (ZDF) rat, an animal model of type 2
K Pabreja et al.
British journal of pharmacology, 171(5), 1114-1128 (2013-07-31)
The incidence of type 2 diabetes in developed countries is increasing yearly with a significant negative impact on patient quality of life and an enormous burden on the healthcare system. Current biguanide and thiazolidinedione treatments for type 2 diabetes have

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service